Sterigenics Invests Over $10M for Expansion
News Jun 20, 2014
Sterigenics International LLC has announced that it will invest more than $10 million to expand operations in Atlanta, Dallas and Belgium.
“Strong global customer demand is driving this expansion,” said Philip Macnabb, President and COO of Sterigenics International LLC. “This past year has seen growing demand for our outsourced sterilization services. We are making these strategic expansions as well as our recently completed acquisition of FTSI, a gamma sterilization operation outside of Tampa Florida, to prepare for anticipated growth in these areas.”
The Sterigenics Atlanta facility, located for more than 20 years in suburban Smyrna, Georgia, will add a 30 pallet Ethylene Oxide chamber, increasing processing capacity two million cubic feet per year. Space will be built out for an additional aeration room to accommodate the increased production. The location offers sterilization of medical products, validation capabilities and SteriPro lab services.
The Sterigenics Dallas facility, located in suburban Grand Prairie, Texas, will increase Ethylene Oxide processing capacity by three million cubic feet per year. A build out will produce expanded pre-conditioning and aeration rooms, with completion by January 2015. Sterigenics has operated at the site since 2003 and offers sterilization of medical products, validation capabilities and SteriPro lab services.
Petit-Rechain, Belgium is one of Sterigenics largest locations, offering Ethylene Oxide sterilization, SteriPro lab services, validation and cycle development capabilities. A 32 pallet chamber will be installed, bringing the total number of chambers to 14. The additional chamber will result in two million cubic feet of additional Ethylene Oxide processing capacity and will be operational by year end.
Headquartered in Deerfield, Illinois, Sterigenics International LLC operates out of 40 facilities across the Americas, Europe and Asia and is a global leader in outsourced contract sterilization services, primarily to the medical device, pharmaceutical, food safety and high performance/specialty materials industries.
As a result of its global service capabilities, and the proprietary Sterigenics GPS® platform that allows real time order tracking and just in time supply chain operation, it counts numerous Fortune 500 companies as clients, with relationships exceeding two decades.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE